Tertiary lymphoid structures were present in 61.3% of the liver tissues obtained from patients with PBC. Tertiary lymphoid structures are characteristics of lymphocyte accumulation in the portal ...

The results showed that PB BAL offered deeper alveolar sampling while avoiding contamination from the larger airways. It also revealed incremental changes in the small airways and alveoli, aiding in ...

In addition to reduced RBC transfusion requirements, hemolysis markers significantly improved with the combined therapy. Results from a phase 2 clinical trial evaluating the use of dose-escalated ...

MF at the time of diagnosis predicts complete molecular response in patients with CML initially treated with imatinib, a study found. Eculizumab treatment may reduce the symptoms of neuromyelitis ...

Test Your Knowledge About the Surgical Management of Myasthenia Gravis Test Your Knowledge About the Histology of Myasthenia Gravis Test Your Knowledge About the Clinical Features of Myasthenia Gravis ...

Patients in the PAH group had a higher prevalence of metabolic abnormalities and hyperparathyroidism, and lower bone mineral density than controls. For physicians who treat pulmonary arterial ...

A patient with PLA2R-positive membranous nephropathy later developed IgG4-related autoimmune pancreatitis and renal masses, which resolved with glucocorticoid therapy. Glucocorticoid therapy ...

Differentiating POEMS syndrome from chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is important because both have similar demyelinating features but require different treatments.

The results correct a misconception in the ACR/EULAR criteria for IgG4-RD that list hypocomplementemia as a feature limited to patients with renal involvement. A new study has found that ...

Eculizumab was started between 35 and 61 days following the onset of the NMOSD attack and partially reduced the symptoms of all 5 patients. Eculizumab treatment may reduce the symptoms of ...

KB-208 demonstrated comparable efficacy to intravenous immunoglobulin for treating immune thrombocytopenia in 3 mouse strains, with significantly lower dosing requirements. KB-208, a small molecule ...